Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing regenerative cell therapies for neurological disorders. The company’s programs are intended to address conditions in which existing treatments may be inadequate, including certain forms of epilepsy and other disorders affecting the central nervous system.

Its lead investigational program, NRTX-1001, is a neural cell therapy being developed for drug-resistant focal epilepsy. The treatment is designed to deliver specialized neural cells that may help restore or regulate disrupted brain activity. NRTX-1001 remains an investigational product and has not been established as safe or effective for commercial use.

Neuphoria’s development activities are centered on advancing its therapeutic pipeline through clinical research and regulatory processes. Publicly available information about the company’s broader operations, geographic reach and executive leadership is limited.

Key Stats

• Today's Range: $3.24 to $3.37
• 50-Day Range: $3.32 to $3.98
• 52-Week Range: $3.19 to $17.90
• Volume: 44,078 shs
• Average Volume: 90,642 shs
• Market Capitalization: $17.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Reduce

Neuphoria Therapeutics Stock Analysis - MarketRank™

Neuphoria Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 436th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Neuphoria Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Neuphoria Therapeutics has a consensus price target of $7.00, representing about 112.5% upside from its current price of $3.29.

Amount of Analyst Coverage

Neuphoria Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($2.43) to ($2.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuphoria Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuphoria Therapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuphoria Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.38% of the float of Neuphoria Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neuphoria Therapeutics has a short interest ratio ("days to cover") of 1.61, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuphoria Therapeutics has recently decreased by 18.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuphoria Therapeutics does not currently pay a dividend.

Dividend Growth

Neuphoria Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Neuphoria Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Neuphoria Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for NEUP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.55% of the stock of Neuphoria Therapeutics is held by insiders.

Percentage Held by Institutions

15.90% of the stock of Neuphoria Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 10/14/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NEUP
• Previous Symbol: NASDAQ:NEUP
• CIK: 1191070
• Web: www.neuphoriatx.com
• Phone: (781) 439-5551
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuphoria Therapeutics: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +116.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.45 million
• Net Margins: N/A
• Pretax Margin: -1,157.67%
• Return on Equity: -38.31%
• Return on Assets: -28.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.83
• Quick Ratio: 27.83

Sales & Book Value

• Annual Sales: $1.17 million
• Price / Sales: 14.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.55 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 5,410,000
• Free Float: 5,327,000
• Market Cap: $17.53 million
• Optionable: N/A
• Beta: 0.75